188 related articles for article (PubMed ID: 21078948)
1. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
Zhou N; Nowicka-Sans B; Zhang S; Fan L; Fang J; Fang H; Gong YF; Eggers B; Langley DR; Wang T; Kadow J; Grasela D; Hanna GJ; Alexander L; Colonno R; Krystal M; Lin PF
Antimicrob Agents Chemother; 2011 Feb; 55(2):729-37. PubMed ID: 21078948
[TBL] [Abstract][Full Text] [Related]
2. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.
Ray N; Hwang C; Healy MD; Whitcomb J; Lataillade M; Wind-Rotolo M; Krystal M; Hanna GJ
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):7-15. PubMed ID: 23614999
[TBL] [Abstract][Full Text] [Related]
3. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
Zhou N; Nowicka-Sans B; McAuliffe B; Ray N; Eggers B; Fang H; Fan L; Healy M; Langley DR; Hwang C; Lataillade M; Hanna GJ; Krystal M
J Antimicrob Chemother; 2014 Mar; 69(3):573-81. PubMed ID: 24128669
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
Hanna GJ; Lalezari J; Hellinger JA; Wohl DA; Nettles R; Persson A; Krystal M; Lin P; Colonno R; Grasela DM
Antimicrob Agents Chemother; 2011 Feb; 55(2):722-8. PubMed ID: 21078951
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
Charpentier C; Larrouy L; Visseaux B; Landman R; Levittas M; Storto A; Damond F; Yazdanpanah Y; Yeni P; Brun-Vézinet F; Descamps D
J Antimicrob Chemother; 2012 Jun; 67(6):1459-61. PubMed ID: 22382470
[TBL] [Abstract][Full Text] [Related]
6. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
[TBL] [Abstract][Full Text] [Related]
7. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
[TBL] [Abstract][Full Text] [Related]
8. A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding.
Wang HG; Williams RE; Lin PF
Curr Pharm Des; 2004; 10(15):1785-93. PubMed ID: 15180540
[TBL] [Abstract][Full Text] [Related]
9. Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.
Soulié C; Lambert-Niclot S; Fofana DB; Fourati S; Ait-Arkoub Z; Sayon S; Simon A; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2013 Jun; 68(6):1243-5. PubMed ID: 23396856
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.
Guo Q; Ho HT; Dicker I; Fan L; Zhou N; Friborg J; Wang T; McAuliffe BV; Wang HG; Rose RE; Fang H; Scarnati HT; Langley DR; Meanwell NA; Abraham R; Colonno RJ; Lin PF
J Virol; 2003 Oct; 77(19):10528-36. PubMed ID: 12970437
[TBL] [Abstract][Full Text] [Related]
11. MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.
Grupping K; Selhorst P; Michiels J; Vereecken K; Heyndrickx L; Kessler P; Vanham G; Martin L; Ariën KK
Retrovirology; 2012 May; 9():36. PubMed ID: 22551420
[TBL] [Abstract][Full Text] [Related]
12. Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
Fofana DB; Charpentier C; Maïga AI; Lambert-Niclot S; Sayon S; Désiré N; Simon A; Yazdanpanah Y; Katlama C; Descamps D; Calvez V; Marcelin AG; Soulié C
J Antimicrob Chemother; 2015 Jan; 70(1):130-5. PubMed ID: 25270328
[TBL] [Abstract][Full Text] [Related]
13. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.
Alessandri-Gradt E; Charpentier C; Leoz M; Mourez T; Descamps D; Plantier JC
J Antimicrob Chemother; 2018 Oct; 73(10):2716-2720. PubMed ID: 30032194
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations.
Alencar CS; Nishiya AS; Ferreira S; Giret MT; Diaz RS; Sabino EC
AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1267-71. PubMed ID: 20977300
[TBL] [Abstract][Full Text] [Related]
15. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
Zhang Y; Chapman JH; Ulcay A; Sutton RE
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
[TBL] [Abstract][Full Text] [Related]
16. Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies.
Zhou N; Fan L; Ho HT; Nowicka-Sans B; Sun Y; Zhu Y; Hu Y; McAuliffe B; Rose B; Fang H; Wang T; Kadow J; Krystal M; Alexander L; Colonno R; Lin PF
Virology; 2010 Jul; 402(2):256-61. PubMed ID: 20400170
[TBL] [Abstract][Full Text] [Related]
17. Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry.
Da LT; Quan JM; Wu YD
Proteins; 2011 Jun; 79(6):1810-9. PubMed ID: 21465559
[TBL] [Abstract][Full Text] [Related]
18. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.
Madani N; Perdigoto AL; Srinivasan K; Cox JM; Chruma JJ; LaLonde J; Head M; Smith AB; Sodroski JG
J Virol; 2004 Apr; 78(7):3742-52. PubMed ID: 15016894
[TBL] [Abstract][Full Text] [Related]
19. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).
McNicholas PM; Mann PA; Wojcik L; Qiu P; Lee E; McCarthy M; Shen J; Black TA; Strizki JM
J Acquir Immune Defic Syndr; 2011 Mar; 56(3):222-9. PubMed ID: 21209592
[TBL] [Abstract][Full Text] [Related]
20. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.
Lin PF; Blair W; Wang T; Spicer T; Guo Q; Zhou N; Gong YF; Wang HG; Rose R; Yamanaka G; Robinson B; Li CB; Fridell R; Deminie C; Demers G; Yang Z; Zadjura L; Meanwell N; Colonno R
Proc Natl Acad Sci U S A; 2003 Sep; 100(19):11013-8. PubMed ID: 12930892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
